TNF and colitis: To explore the response of DRGs to biologic therapies, such as TNF-α inhibitors golimumab (GLM), infliximab (IFX), and vedolizumab (VDZ), we analyzed the GSE92415 and GSE73661 datasets, which include colon biopsy samples from patients with moderate to severe colitis.